Horizon Pharma (HZNP): Contracting Activity Picking Up - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
August 2, 2016 12:38 PM EDTBMO Capital affirms Horizon Pharma (Nasdaq: HZNP) at Outperform with a price target of $29 after the company announced that two of its primary care products Duexis and Vimovo were removed from the 2017 CVS/Caremark exclusion list.
Analyst Gary Nachman commented today, We view this announcement as an important win for HZNP. It demonstrates that it is improving its execution on the managed care front as... More
